PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ESC Congress Rome 2016
News from AHA Scientific Sessions 2016
Late Breaking Lipid Trials: Future Bodes Bright for PCSK9

GLAGOV: Greater LDL-C lowering with the PCSK9 inhibitor evolocumab on a statin background leads to greater plaque regression.

View the results here »

PCSK9 Forum Editors discuss the implications of GLAGOV in this Editorial

Read the report »
John Chapman Henry Ginsberg

ORION-1: PCSK9 RNA interference agent inclisiran (previously known as ALN-PCSsc) continues to look good, with durable LDL-C lowering over 4-6 months.

View the results here »
New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

Read online » Download now »

Forward to colleagues »
  New eBook
Click here to forward this email to a colleague
Questions & Answers
Why are new treatments needed?
Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.